Richard A. Scolyer

The University of Sydney — Australia

Medicine · Health Sciences

141h-index110.4kcitations1.7kworks5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(702), Melanoma and MAPK Pathways(497), Cancer Immunotherapy and Biomarkers(433), Immunotherapy and Immune Responses(310), CAR-T cell therapy research(264)

Publications1.7k total

Supplementary Data1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
2025Open Access
Supplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
2025Open Access
A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making
Journal of the American Academy of Dermatology·2025Open Access
Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
2025Open Access
Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Tables 1 and 6-8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S7 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Supplementary Figure S3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
2025Open Access
Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Table 4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
page 1 of 83Next →

Frequent Co-authors

Georgina V. Long(31), John F. Thompson(22), Alexander M. Menzies(18), Richard Kefford(16), James S. Wilmott(13), Robyn P.M. Saw(12), Matteo S. Carlino(10), Helen Rizos(10), Andrew J. Spillane(6), Graham J. Mann(6), Serigne Lo(6), Lauren E. Haydu(5), Varsha Tembe(5), Gulietta M. Pupo(5), Tuba N. Gide(5), Jason Madore(5), Alexander Guminski(5), Alexander C. J. van Akkooi(5), Kerwin F. Shannon(5), Jenny Lee(5)